Alentis Therapeutics Alternatives & Competitors
12 companies similar to Alentis Therapeutics — We develop breakthrough treatments for Claudin1-positive tumors and organ fibros...
Companies similar to Alentis Therapeutics
ImmunoMet Therapeutics, Inc.
Targeting Metabolic Reprogramming in Fibrosis and Oncology
Germany
Mersana Therapeutics
Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for p...
Cambridge, United States
Antharis Therapeutics, Inc.
Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting...
San Diego, United States
Rival Readout
Competing with Alentis Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
ADC Therapeutics
Innovating Science. Inspiring Hope.
Lausanne, Switzerland
Agomab
Unlocking Disease Modification in Fibro-Inflammation
Ghent, Belgium
ImmunoGen
Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, a...
Bicara Therapeutics
Pioneering bifunctional antibodies for targeted tumor modulation
Boston, United States
Cybrexa Therapeutics
Changing the paradigm for cancer treatment through the development of antigen-independent...
New Haven, United States
NBE-Therapeutics AG
Next generation antibody drug conjugates
Basel, Switzerland
Tyra Biosciences
TYRA is focused on developing next-generation precision medicines that target large opport...
Carlsbad, United States
Arcus Biosciences
Biopharmaceutical company developing differentiated molecules and combination therapies fo...
Hayward, United States
About Alentis Therapeutics
Alentis Therapeutics, founded in 2019, is a pioneering clinical-stage biotechnology company with a focus on developing breakthrough treatments for Claudin1-positive tumors and organ fibrosis. The company is based in the pharma-biotech hub of Basel, Switzerland. The company specializes in first-in-class antibody-drug co...
Development of anti-Claudin-1 ADCs, Clinical trials for monoclonal antibodies, Fibrosis study results publication, Leadership in therapeutic development
Cancer patients, Patients with organ fibrosis, Healthcare professionals, Biotech investors
Claudin-1, Tumor Treatment, Organ Fibrosis, Antibody-drug Conjugates, Oncology, Liver Fibrosis, Kidney Fibrosis, Lung Fibrosis, Cancer Therapy, Clinical-stage Biotechnology, Multi-organ Fibrosis, Drug Discovery, Drug Development, Rare Diseases, Nephrology
B2B
Licensing, Performance Based, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Alentis Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Alentis Therapeutics on 28 Jan 2026. The 12 companies listed here were last checked between 27 Nov 2025 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
